glp-1 cardiovascular outcomes trial results august 2025 Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials - Yin - GLP-1 Receptor Agonist Market Valued

(Note: While oral Epsom salt is an approved laxative, we recommend it strictly as a bath soak for GLP-1 users due to its harsh effects on an already sensitive stomach)

When paired with healthy habits, it may assist with steady weight management and overall vitality

Both expected in 2026

Iron deficiency develops in a meaningful percentage of patients on GLP-1 receptor agonists like semaglutide, often appearing 3-6 months into treatment

This narrative review outlines the rationale for their use in KTRs, drawing from recent trials in non-transplant populations and emerging real-world evidence in KTR We recommend reading this article